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Vasculitis and Vasculopathies
Ana Paula Urzedo, Mariane Martins Manso  
and Thaisa Macarini de Faria
Abstract
Our organism, as complex as it is, needs a giant vascular network to deliver 
nutrients to all cells, so vasculopathies and vasculitis are diseases present in all 
medical specialties. The skin and subcutaneous cellular tissue are irrigated by a vast 
vascular network, with cutaneous involvement related to these frequent patholo-
gies. These can be restricted to the integumentary system or be part of systemic 
diseases with cutaneous manifestations, which make them of great interest to 
dermatologists. They can affect any caliber of vessels and present with several 
dermatological manifestations such as erythema, livedo reticularis, palpable 
purpura, nodules, ulcers, urticaria, hemorrhagic blisters, gangrene and other 
manifestations that can be isolated or associated with systemic signs and symptoms. 
However, there is no worldwide consensus regarding the classification of vasculitis, 
and the classification proposed in this chapter is based on the International Chapel 
Hill Conference Nomenclature of Vasculitides 2012, which is based on the size of 
the vessels. The purpose of this chapter is to compile a review of the most current 
treatments for these conditions.
Keywords: vasculitis, lymphocytic, cutaneous small vessel, systemic vasculitis, 
leukocytoclastic, cutaneous, vascular diseases
1. Introduction
Vasculitis and vasculopathies are a group of diseases that course with an inflam-
matory process, which attacks vascular endothelium of vessels of different calibers. 
Usually, they course with dermatology lesions, the diagnosis is difficult, and they 
have a few treatment options. Despite that, an early diagnosis can contribute to a 
better quality of patient’s life and prevent further complications (Figure 1) [1].
2. Methods
The authors performed a bibliographic review from cutaneous vasculitis and 
vasculopathies from literature, including online academics platforms such as PubMed 
and Google Scholar and dermatology books as Rivitti and Fitispack. The keywords used 
from this chapter were cutaneous vasculitis, Takayasu arteritis, Giant Cell Arteritis, 
Polyarteritis Nodosa, Kawasaki Disease, Microscopic polyangiitis, Granulomatosis  
with Polyangiitis (Wegener’s), Eosinophilic Granulomatosis with Polyangiitis  
(Churg-Strauss), Cryoglobulinemic Vasculitis, Urticaria Vasculitis, Henoch-Schönlein, 
Behçet’s syndrome, Cutaneous leukocytoclastic angiitis, cutaneous vasculopathies, 
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Phospholipid Antibody Syndrome, Blue Finger Syndrome, Acrocyanosis and others. 
The final objective was summing up the dermatology vasculitis and vasculopathies and 
helping physicians in early diagnosis and treatment.
3. Cutaneous vasculitis
Cutaneous vasculitis may affect vessels of different calibers, especially small and 
medium in the skin and the subcutaneous tissue, resulting in just a small cutaneous 
lesion until serious systemic commitment. Nevertheless, the classification is not 
a consensus. In general, they are classified using clinical criteria, size of the ves-
sels, histopathological exams, laboratorial findings and etiologic agents [3, 4]. In 
2012, the Chapel Hill Consensus Conference (CHCC) proposed a new classification 
from the most used since 1994, removing many eponymous. The classification is a 
strategic pillar to help choose the right path to lead these patients through the right 
treatment [4, 5] (Table 1).
3.1 Large vessel vasculitis
3.1.1 Takayasu arteritis
It is a large vessel vasculitis whose etiologic agent is unknown. It is more fre-
quently found in young Asiatic women, in the proportion from 5 to 12 W:1 M, and 
usually affects the aorta and its main branches. It is not a rare disease but is not as 
usual as arteritis of giant cells. The diagnosis is usually late because these patients 
develop many collateral arteries, they have nonspecific symptoms and the develop-
ment of these affections is very slow. Pregnancy in patients affected by Takayasu 
arteritis is a troubling problem because it affects women of childbearing age, and it 
will cause risks to the mother and the child. The arteritis could be associated with 
Crohn’s and rectocolitis disease [6].
Figure 1. 
Purpuric macules and papules coalescing into patches (A) in small vessel vasculitis and fixed livedo reticularis 
and subcutaneous nodules (B) in medium vessel vasculitis (polyarteritis nodosa) [2].
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The more effective treatments are oral corticosteroids, but there are many 
relapses when corticosteroids taper. High doses of corticosteroids (40–60 mg/day 
of prednisone or equivalent) should be initiated immediately after the diagnosis to 
induce remission. During disease remission, it is necessary sparing the drug until 
15-20mg/day for two or three months, and after a year decrease the doses to 10mg/
day or less. The immunosuppressive agents are used as corticoid sparing agents such 
as methotrexate, azathioprine, leflunomide, mycophenolate mofetil and cyclophos-
phamide [6]. There are evidences that biological agents such as anti-TNF-alpha, 
tocilizumab and rituximab could be effective in refractory cases, but more trials 
are necessary to evaluate the effectiveness of these drugs [8]. In addition, patients 
with ischemic problems need endovascular interventions. The mortality range is 
between 3 and 21% [6].
3.1.2 Giant cell arteritis (GCA)
It is a systemic vasculitis of large vessels, with tropism to the aorta and its 
branches, mainly external carotid. It is a most common vasculitis in above 50-year-
olds and affects more women than men (3 W:2 M). The corticosteroids are the most 
common therapeutic used in these cases. In the beginning, we need high doses of 
corticosteroids to control the inflammation, and then it could be used sparingly 
Classification Diseases
1 Large vessel vasculitis Takayasu arteritis
Giant cell arteritis
2 Medium vessel Polyarteritis nodosa
Kawasaki disease
3 Small vessel vasculitis
ANCA-associated vasculitis
Microscopic polyangiitis
Granulomatosis with polyangiitis (Wegener’s)
Eosinophilic granulomatosis with polyangiitis 
(Churg-Strauss)
4 Small vessel vasculitis
Immune complex
Antiglomerular basement membrane disease
Cryoglobulinemic vasculitis (CV)
Hypocomplementemic urticarial vasculitis (anti-C1q 
vasculitis)
IgA vasculitis (Henoch-Schönlein)
5 Variable vessel vasculitis Behçet’s syndrome
Cogan’s syndrome
6 Single-organ vasculitis Cutaneous leukocytoclastic angiitis
Cutaneous arteritis
Primary central nervous system vasculitis
7 Vasculitis associated with systemic 
disease
Lupus vasculitis
Rheumatoid vasculitis
Sarcoid vasculitis
Others
8 Vasculitis associated with probable 
cause
Hepatitis C virus-associated CV
Hepatitis B virus-associated vasculitis
Syphilis-associated aortitis
Drug-associated immune complex vasculitis
Drug-associated ANCA-associated vasculitis
Cancer-associated vasculitis
Others
Table 1. 
2012 International Chapel Hill Consensus Conference Nomenclature of Vasculitides [3].
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until controlled in the patient. These strategies are valid for simple and complicated 
forms of the disease [7].
Simple form is defined by cephalic isolated symptoms with visual disturbance 
or changes in central nervous system. Nowadays, the gold standard treatment is 
oral prednisone or equivalent 40–60 mg/day, and methylprednisolone is not used 
anymore. The initial dose recommended is 0.7 mg/kg day of prednisone and the 
maximum dose is 80 mg/day [7].
The complicated form is defined when there is an ophthalmologic or a central 
nervous or extracephalic complication, mainly aorta and its branches. In these 
cases, methylprednisolone in pulses of 500 mg−1 g a day shall be used for 1 to 5 
consecutive days. During maintenance, some authors believe in doses less than 
5 mg/day. The American Society of Ophthalmology recommends pulses of intrave-
nous methylprednisolone, when patients have ophthalmologic symptoms, but the 
Rheumatology Society prefers oral corticosteroid [7].
It is strategic to introduce corticosteroid-sparing drugs when the disease course 
is lasting long. Methotrexate is the most used treatment and with more evidence 
levels. There are four trials with methotrexate as a sparing drug, but the doses and 
the management are variable from 7.5–15 mg/week [7].
Cyclophosphamide has demonstrated effectiveness in patients dependent on 
corticosteroids or resistant to treatment. It is necessary to give more than 20 mg/day 
for 6 months or 10 mg/day for 1 year or more. The dose from 500 mg/m2 or 500 mg/
injection in 6 courses is standard from 5 months on average. It is highly important to 
warn patients of several side effects such as bone marrow suppression [7].
Azathioprine therapy has less controlled studies. Some studies showed a modest 
improvement. Hydroxychloroquine, an antimalarial synthetic drug, was tested also. 
One French study divided patients into two groups: one took prednisone 0.7 mg/
kg/day in the beginning associated with hydroxychloroquine (400 mg/day) and the 
control group just received prednisone and placebo. The group that had hydroxy-
chloroquine and corticoid had usually stopped later the prednisone and they had 
more relapses [7].
Nowadays, one option is biologics medicines. Anti-TNF-alpha does not have 
enough studies that showed control of the disease with this class of medication [7]. 
Tocilizumab, a humanized antibody that blocked membranous and soluble recep-
tors of IL-6 (IL-6R), is a current option since IL-Il-6 is implicated in the etiopatho-
genesis of this affection. Three main studies evaluated the efficacy of the drug, 
although the therapeutics was different between these studies [7, 8].
A randomized control trial with 30 patients had tested 20 patients receiving 
corticoids and tocilizumab (8 mg/kg every 4 week during a year), and 10 received 
corticoids and placebo. The survival without relapses during a year was highest in 
patients treated with tocilizumab. However, there are no data available after the 
medication was stopped [7, 8].
Another promising biotherapy is abatacept. This medication with corticoids 
could decrease the risk of relapses, although more data is necessary to corroborate 
this hypothesis.
Ustekinumab, a subunit against anti-p40 IL-12/23 targeting Th1 and Th17 
responses, has been showing similar side effects as corticoids. Some patients, who 
had refractory disease, have been treated with anakinra and they achieved success. 
Anakinra is a biopharmaceutical drug that blocks IL-1. All patients who had taken 
the drug had shown improvement in inflammation biomarkers and/or in their 
symptoms, with the disappearance of arterial inflammation in PET/CT. More stud-
ies are necessary though [7].
Other pharmacological drugs can be used as adjuvant treatments such as anti-
platelets and anticoagulants, but there is no official recommendation about these 
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drugs in the treatment of GAC. The statins do not influence the evolution of the 
disease, but they are used to prevent cardiovascular risk. Furthermore, these drugs 
could have an anti-inflammatory role via the inhibition of TH17 pathway [7].
3.2 Medium vessel vasculitis
3.2.1 Polyarteritis nodosa (PAN)
It is a rare necrotizing systemic vasculitis that affects small- and medium-sized 
vessels and is not usually associated with ANCA [8, 9], although there are reports 
in the literature of patients with PAN and positive ANCA. Several treatments are 
suggested for this condition, and the control is still a challenge [9].
Cutaneous involvement and peripheral nerves are the favorite sites of the 
disease, cutaneous and gastrointestinal vasculitis have specific histopathological 
characteristics, and until now, it has no development glomerulonephritis described. 
Gastrointestinal tract involvement is common and is one of the predictors of 
disease morbidity and mortality. There is cutaneous PAN without systemic involve-
ment, and it very rarely progresses to the systemic form of the disease. According 
to the new classification, PAN is subdivided into idiopathic PAN and hepatitis 
B-associated PAN [9].
Treatment of PAN is usually based on the combination of systemic corticoste-
roids and immunosuppressants. The most commonly used medications are cyclo-
phosphamide, azathioprine, methotrexate or mycophenolate mofetil [9].
The use of biological medications is reserved for cases of refractory PAN with-
out association with hepatitis B. The use of rituximab, an anti-CD20 monoclonal 
antibody, has not been formally indicated for patients with PAN, but its use is 
supported in patients with ANCA-associated vasculitis. There are case reports using 
anti-TNF-alpha, such as etanercept and infliximab, and tocilizumab, but only in 
refractory cases [8].
3.2.2 Kawasaki disease (DK)
It is a systemic vasculitis, common in male child, with fever, rash, non-
exudative bilateral conjunctivitis, oral and pharyngeal mucosal erythema, cervical 
lymphadenopathy, and it can affect the extremity. They may have fewer common 
symptoms such as pyuria, meningitis, shock and retropharyngeal or parapharyn-
geal abscess [10].
The etiology of Kawasaki disease is unknown. The diagnosis of Kawasaki disease 
is based on the presence of fever for ≥5 days, along with the presence of at least 4 of 
the 5 main clinical features [10] (Table 2).
Clinical features
1 Erythema and cracking of the lips, strawberry tongue and/or pharyngeal and oral mucosa 
erythema
2 Bilateral bulbar conjunctival injection without exudate
3 Rash
4 Erythema and edema of the hands and feet in the acute phase and/or periungual scaling in the 
subacute phase
5 Cervical lymphadenopathy (≥1.5 cm in diameter), usually unilateral
Table 2. 
Clinical features in Kawasaki disease [10].
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Patients who have met the diagnostic criteria are considered to have complete 
Kawasaki disease (also referred to as typical or classic Kawasaki disease). Patients 
who do not have enough major clinical findings can be diagnosed with incomplete 
Kawasaki disease [10].
Intravenous immunoglobulin (IVIG) is the basis for treatment. Usually, it is 
initiated before 10 days of fever and significantly reduces coronary artery aneu-
rysms (CAAs) that decrease from 25% to less than 5%. Around 10–30% of patients 
are resistant to IVIG treatment [10].
Unfortunately, in some cases, IVIG is discontinued or administered at a reduced 
dose due to cost. Evidence for therapies beyond IVIG is limited, with no evidence-
based recommendations for the management of patients with resistance to initial 
IVIG treatment.
In the initial treatment, if the patient is in the acute phase treatment, aspirin 
(30–50 to 80–100 mg/kg/day) and IVIG (2 g/kg) are recommended. The treat-
ment of patients with resistance (persistent or recurrent fever after the end of 
IVIG after 24 hours) is to initiate IVIG 2 g/kg, associated to corticosteroids and/or 
infliximab [10, 11].
The use of corticosteroids is controversial due to the cardiovascular risk in 
prolonged use.
Anti-TNF-alpha is also recommended for patients with coronary artery 
aneurysms, and in the minority of cases, it can be used in patients without 
aneurysms. Other therapies possible are anti-interleukin 1, canakinumab and 
cyclosporine [11].
3.3 Small vessel vasculitis (SVV)
3.3.1 Microscopic polyangiitis
Microscopic polyangiitis is an ANCA-associated vasculitis with significant 
morbidity and mortality. Treatment follows the same protocol as granulomatosis 
with polyangiitis [12].
3.3.2 Granulomatosis with polyangiitis (Wegener’s)
It is another necrotizing systemic vasculitis that affects small and medium 
vessels and is often associated with ANCA. It occurs in patients between 45 and 
60 years old from both genders and is rarely observed in Negroids. The main fea-
tures are the involvement of the upper and lower respiratory tract and the kidneys. 
Ears, nose and throat may develop with sinusitis and crusted rhinorrhea that are 
usually severe. Pulmonary nodules and renal involvement with crescent glomerulo-
nephritis can be seen [13, 14].
It is a serious disease, and if left untreated, it almost always progresses to death. 
With the advent of new therapies, 90% of patients evolve to remission and the survival 
rate is 80% in 10 years. The first phase, known as the induction phase, aims to put the 
patient into remission, and it lasts between 3 and 6 months according to the clinical 
response. The second phase is known as the maintenance phase trying to consolidate 
the first phase and prevent relapses. It lasts from 12–24 months [13] (Figure 2).
In induction, prednisone 1 mg/kg is recommended. For severe forms, methyl-
prednisolone pulse is indicated at doses of 7.5–15 mg/kg/day for 1–3 consecutive 
days. After 3–4 weeks of treatment, the corticosteroid dose is gradually decreased, 
but without reaching doses of less than 15 mg/day until 4th month. The combina-
tion of two immunosuppressants in the induction phase is essential for severe or 
refractory patients such as cyclophosphamide or rituximab.
7Vasculitis and Vasculopathies
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Cyclophosphamide is preferred if rapid renal failure occurs at a dose of 
600 mg/m2 (maximum 1.2 g/bolus) every 2 weeks for 1 month (day+1, day+15, 
day+30) and then 700 mg/m2 every 3 weeks until remission (average of 6–9 cycles 
in total).The dose can be adjusted for age and renal function (500 mg/m2 in the 
presence of renal failure and 500 mg fixed dose every 3 weeks—maximum 6 
bolus) [13, 14].
Rituximab is the choice for pregnant women or patients who have failed 
cyclophosphamide or have relapsed. It is used at a dose of 375 mg/m2 per week for 
4 weeks. Plasmapheresis may be used in severe forms of the disease with severe 
renal involvement (Cr > 500 μmol/L) or alveolar hemorrhage. Also, corticosteroid 
therapy can be associated with immunosuppressants [13, 14].
For localized or not very severe cases, methotrexate (20–25 mg per week) is 
an option. The AGATA study demonstrated efficacy of abatacept (1 mg/kg IV 
on day+1, day+29 and then once per month) combined with prednisone and an 
immunosuppressant (azathioprine, methotrexate or mycophenolate mofetil) for 
recurrent and limited forms.
Maintenance lasts between 18 and 24 months after remission has been achieved. 
Corticosteroids may be combined with azathioprine (2 mg/kg/day) or methotrexate 
(20–25 mg/week) [13].
Treatment with sulfamethoxazole/trimethoprim (400/800 mg) is given to 
prevent relapse from Pneumocystis jirovecii infection. Patients should be vaccinated 
following the regional schedule and is contraindicated live virus vaccines [13]. 
Staphylococcus aureus was the most identified pathogen in positive cultures, and it is 
important to remember that it also deserves prevention [14].
3.3.3 Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
Eosinophilic granulomatosis polyangiitis (EGPA), also known as Churg-Strauss 
disease, is characterized by patients with asthma, eosinophilia and necrotizing vas-
culitis with extravascular eosinophilic granulomas that affect small and large vessels. 
It is a vasculitis associated with ANCA (neutrophilic cytoplasmic antibodies) and 
Figure 2. 
Necrotic vascular purpura (black arrows) of the upper limbs in granulomatosis with polyangiitis-Wegener’s [13].
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the rarest vasculitis within the group of ANCA-associated vasculitis, and that is why 
there are no highly recommended treatments based on the literature [15].
Corticosteroids are usually used to induce remission of the disease as well as 
immunosuppressants, for example cyclophosphamide in more severe cases. Long-
term maintenance of immunosuppressants is used to prevent disease recurrence, 
but their long-term efficacy is discussed. Azathioprine has been recommended as 
maintenance therapy. The efficacy of mepolizumab, an anti-IL5 monoclonal anti-
body, has been recommended for these patients alone or in combination with cor-
ticotherapy. Others monoclonal anti-IL5, reslizumab and benralizumab drugs are 
still being studied. Studies suggest that rituximab may be effective in EGPA. Other 
drugs such as IFN-α appear to be effective in remission induction and maintenance; 
however, the safety profile restricts their use. Drugs such as anti-IgE (omalizumab) 
are used to control asthma, but their effects are unknown in the treatment of vascu-
litis. High doses of immunoglobulin have also been used to induce disease remission 
with good results. Intravenous immunoglobulin may be effective in treating residual 
peripheral neuropathy [15].
3.4 Immune complex SVV
3.4.1 Cryoglobulinemic vasculitis
Cryoglobulins are cold precipitated immunoglobulins that can cause vasculitis 
and vasculopathy. Type I cryoglobulins are responsible for 10–15% of symptom-
atic vasculitis cases and are related to malignant hematological disorders such as 
myeloma, B-cell lymphoma or undetermined monoclonal gammopathy (MGUS). 
Mixed cryoglobulins correspond to 80–85% of cases and are associated with infec-
tious diseases, especially chronic hepatitis C, B-cell malignancies and autoimmune 
diseases such as Sjögren’s syndrome and lupus. Vasculitis is most associated with 
mixed cryoglobulins. Women are affected more than men 2:1 [12].
In symptomatic patients with cryoglobulinemia type I, it is indicated to treat the 
hematologic basis diseases. Lymphomas require a combination of chemotherapy 
and myeloma treatment with drugs such as bortezomib, thalidomide, lenalido-
mide and other alkylating agents. Bone marrow transplantation can be performed 
in patients with cryoglobulinemia-associated myeloma. MGUS can be treated 
with the same myeloma drugs; however, rituximab has been the drug of choice. 
Plasmapheresis may be used for patients with severe renal involvement or extensive 
lower limb necrosis. Avoiding exposure to cold is essential [12].
Mixed cryoglobulins, usually hepatitis C-associated cryoglobulinemic vasculitis, 
are well-treated as suppression of hepatitis C replication occurs. Studies reported 
between 2011 and 2013 associated with pegylated interferon (PegIFN) and ribavirin 
for 12 months achieved a 50–60% control response to hepatitis C. The introduction 
of antiviral agents dramatically changed cryoglobulinemia-associated vasculitis. 
They promote shorter treatment without the need for interferon and with responses 
greater than 95% associated with few adverse effects. The drugs used are sofosbuvir, 
simeprevir, ledipasvir and daclatasvir, that can be associated with ribavirin. In 
some cases of more severe vasculitis, low doses of rituximab and other immunosup-
pressants may be used in selected cases. Rituximab targets B-cell populations that 
produce cryoglobulins and treats severe vasculitis [12] (Figure 3).
3.4.2 Urticaria vasculitis
The term urticaria vasculitis is used for plaques of urticaria that present leuko-
cytoclasia on histopathological examination. It is a clinical pathological diagnosis, 
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characterized by a skin inflammation of the dermis capillaries and postcapillary 
venules, with a range of clinical signs from hives picture to a well-established vascu-
litis. Like any vasculitis, it can affect the skin and other organs, including skeletal, 
pulmonary, renal, gastrointestinal, cardiac and ophthalmic systems. The disease is 
spectral, ranging from mild to severe [16, 17].
Related etiological factors are infections, medications, autoimmune reactions, 
malignancies or idiopathic reasons. It can be classified as normocomplementemic or 
NUV that presents normal levels of complement, usually not with systemic involve-
ment, and hypocomplementemic or HUV that has low complement levels and may 
have systemic involvement [17].
The treatment of vasculitis urticaria is a challenge, and there are no guidelines 
for the management of this disease. There are reports in the literature of the use of 
hydroxychloroquine and colchicine, which are as effective as systemic corticoste-
roids [16, 18].
Immunosuppressive drugs are used such as azathioprine, mycophenolate mofetil 
or cyclophosphamide. Rituximab with the usual doses also seems to have a good 
response. To manage the symptoms, sedative and nonsedating antihistamines may 
be used if urticaria is prominent. However, it is not usually effective. Nonsteroidal 
anti-inflammatory drugs are very useful in these cases such as naproxen, indo-
methacin and ibuprofen [13, 16].
Another alternative therapy is to combine corticosteroids up to 1 mg/kg and 
another immunosuppressant (methotrexate, mycophenolate mofetil, azathioprine, 
cyclosporine and very rarely cyclophosphamide). Recent reports include rituximab, 
anakinra, canakinumab and omalizumab as therapeutic arsenal [17].
Figure 3. 
Clinical manifestations of cryoglobulinemic vasculitis; (a) severe skin ulcer; (b) nerve biopsy specimen 
showing vasculitis with a perivascular inflammatory infiltrate; (c) distribution of the peripheral 
neurological involvement indicating length dependency; (d) renal biopsy showing membranoproliferative 
glomerulonephritis; (e) magnetic resonance imaging of the brain showing vasculitis [12].
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3.4.3 Immunoglobulin A vasculitis (Henoch-Schönlein purpura)
It is the most common small vessel vasculitis of childhood, with a predominance 
of IgA deposits. Typically, it involves the skin, intestines and glomeruli and may be 
associated with arthralgia and/or arthritis. In most patients, only supportive treat-
ment is required and analgesia [19, 20]. The disease regresses spontaneously most 
often within 4 weeks, but in some cases, it may last for more than 6 weeks [19]. 
In these cases, the therapeutic options may be dapsone (on average 1–2 mg/kg) or 
colchicine, but there are still no randomized controlled trials with the optimal dose 
and duration of treatment [18, 21]. Some patients require treatment with systemic 
corticosteroids, such as nephritis, orchitis, cerebral vasculitis, pulmonary hemor-
rhage and severe gastrointestinal involvement [19].
Other therapies used are the addition of cytotoxic immunosuppressants, intra-
venous immunoglobulins and plasmapheresis [20]. In case of severe rectal pain or 
abdominal pain, the use of systemic corticosteroids is recommended [19, 20].
The recommended doses for prednisolone are 1–2 mg/kg/day for 1–2 weeks 
followed by weaning. In severe cases, it is possible also to use methylprednisolone 
pulses 10–30 mg/kg maximum 1 g/day for 3 consecutive days. Corticosteroid 
prophylaxis to decrease the chance of developing nephritis is not indicated. There is 
evidence showing that the use of angiotensin-converting enzyme inhibitors (ACE 
inhibitors) may have beneficial effects in patients with proteinuria. In patients with 
proteinuria longer than 3 months, regardless of whether they are receiving predni-
sone or another immunosuppressive drug, the use of ACE inhibitors or angiotensin 
receptor blockers is recommended to prevent and/or limit secondary glomerular 
injury. The first choice for mild nephritis treatment is prednisolone. If proteinuria 
persists, azathioprine, mycophenolate mofetil, cyclosporine or other corticosteroid-
sparing treatment can be started. Also, IV methylprednisolone pulses can be 
considered.
In the treatment for moderate nephritis, the first line is oral, or IV prednisolone, 
or IV methylprednisolone. Azathioprine, mycophenolate mofetil IV or cyclosporine 
may be used according to renal histopathological findings [19].
The treatment for severe nephritis however is high doses of corticosteroids and 
IV cyclosporine to induce remission, and low doses of corticosteroids associated 
with azathioprine or mycophenolate mofetil as maintenance treatment [19].
3.5 Variable vessel vasculitis
3.5.1 Behçet’s syndrome
Behçet’s syndrome has been known since ancient times and was described by 
Hippocrates, but it was reported as a separate disease by Huluci Behçet in 1937. It is 
currently classified as a vasculitis belonging to the subgroup of variable vessel vas-
culitis. It was initially reported in countries bordering the silk route, but nowadays, 
it is found all over the world. The most common manifestation is oral apotheosis 
and is seen in over 90% of cases [22].
It is characterized by progressing multiple attacks and remissions. The duration 
of remission may vary from one attack to another and from one system to another. 
The attack, in most cases, is followed by a complete recovery called Restitutio ad 
Integrum of the tissue. A good example is oral aphthosis, and it is exceptional to 
see a scar. In case of oral aphthosis, it is uncommon to have a scar. In other organs 
such as the eyes, central nervous system and vascular system, we usually observe 
sequelae, which may even progress to death. In these cases, aggressive treatment is 
mandatory [22].
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Treatment will vary depending on systemic involvement. Mucocutaneous mani-
festations do not require aggressive treatment, only topical treatment. Arthritis 
goes on with outbreaks and remissions, which can last from weeks to months, but 
usually respond well to nonsteroidal anti-inflammatory drugs (NSAIDs). Usually, 
the remission in these cases is long and the patient may discontinue the medication. 
There is usually no progression to destruction and deformities [22, 23].
Treatment of the gastrointestinal tract depends on the severity. For other 
manifestations, aggressive treatments are often required, starting with cytotoxic/
immunomodulatory drugs associated with corticotherapy. Eventually, biological 
drugs are used such as apremilast [23].
When the patient suffers from eye involvement, infliximab or adalimumab 
anti-TNF drugs may be considered as first- or second-line therapies, or in the exac-
erbation of pre-existing disease. The European League first recommends cortico-
steroid-associated azathioprine therapy in all patients with subsequent involvement 
and the addition of cyclosporine or infliximab, or switching to interferon alfa with 
or without corticosteroids in patients with severe involvement as more than two 
drop lines in visual acuity on a 10/10 scale and/or retinal disease (retinal vasculitis 
or macular involvement) [23]. Other biological drugs are being studied such as IL-1 
and IL-6 blockers [8].
Intravitreal use of fluocinolone acetonide also has been suggested in refractory 
cases. In these cases, the increased intraocular pressure and infections should 
be monitored. With the higher cause of morbidity and mortality, it is vascular 
involvement. It can affect arteries and veins of any caliber, and with various 
presentations such as thrombosis, occlusions and aneurysms. Immunosuppressive 
therapy is one of choices in these cases and there is no consensus regarding antico-
agulants [23].
A retrospective multicenter study demonstrated a decrease in relapse in immu-
nosuppressant versus untreated patients. Behçet-associated Budd-Chiari syndrome 
has a high mortality rate, and monthly cyclophosphamide pulses associated with 
corticosteroid therapy are the treatment of choice. Anti-TNF-alpha was used in 5 
patients with refractory disease. Two of these patients already had terminal liver 
disease during infliximab administration and died due to liver failure. Two patients 
were successfully treated with infliximab and the fifth patient was stable with 
etanercept but had dural sinus thrombosis during follow-up [23].
3.6 Single-organ vasculitis
3.6.1 Cutaneous leukocytoclastic angiitis
Cutaneous leukocytoclastic angiitis is an inflammation of small vessels, charac-
terized by an inflammatory infiltrate associated with leukocytoclasia by neutrophil 
fragmentation and fibrinoid necrosis in small vessel postcapillary venules. It is the 
most common histological type of cutaneous vasculitis and usually is idiopathic, 
although antibiotics are also linked [24]. It is often clinically manifested by a 
palpable purpura, which is found anywhere on the body, but usually affects more 
lower limbs and can cause arthralgia [24, 25].
Several symptomatic treatments may be proposed to patients: analgesics, 
nonsteroidal anti-inflammatory drugs and antihistamines. For chronic or persistent 
vasculitis, dapsone and/or colchicine may be effective. The use of colchicine in 
the treatment is beneficial through its effect on reducing neutrophil chemotaxis, 
blocking leukocyte adhesion and stabilizing lysosomal membranes. Colchicine at 
a dose of 0.6–1.8 mg/day induces resolution within 1–2 weeks, according to several 
authors [18].
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The best indication for colchicine is in moderate severity vasculitis. It is an 
effective and inexpensive treatment that can be used alone or in combination. 
However, its prescription is sometimes limited because of its gastrointestinal side 
effects [18].
In cases of severe skin necrosis and/or systemic manifestations, systemic cor-
ticotherapy (prednisolone or prednisone 20–60 mg/d) with progressive weaning 
may control the situation in some cases. For patients with systemic manifestations, 
initial therapy should include high doses of corticosteroids and/or cyclophospha-
mide. Intravenous immunoglobulins may be useful in the treatment of severe and 
refractory disease in patients who have a contraindication to traditional immuno-
suppressive therapy [26].
Other drug-associated vasculitis, autoimmune diseases or even infectious 
diseases require treatment of the underlying disease. In some cases, systemic 
corticosteroid therapy is necessary, and corticosteroid-sparing immunosuppressive 
drugs and even intravenous immunoglobulin may be required [26].
4. Cutaneous vasculopathies
Vasculopathies are diseases that present a hyperactivity of blood vessels in the 
skin with systemic repercussions, but of unknown etiology. They are usually clas-
sified as diseases with circulatory disorders such as acrocyanosis, livedo reticularis, 
Raynaud’s phenomenon, erythromelalgia, vessel occlusion leading to necrosis such 
as atherosclerosis obliterans, Buerger’s disease, lymphocyte-mediated inflammatory 
changes such as livedoid vasculitis, malignant atrophic papulosis and neutrophil-
mediated inflammatory changes such as pyoderma gangrenosum. Below, the most 
common representatives will be discussed [27].
4.1 Antiphospholipid antibodies syndrome (APS)
Antiphospholipid antibodies syndrome or Hughes syndrome is a systemic, auto-
immune disease in which there are repeat thrombotic events, repeated fetal losses 
and positive autoantibodies such as anticardiolipin and lupus anticoagulant. As 
skin manifestations, ulcerations and livedo reticularis are the most common signs 
[27, 28]. Some authors relate Sneddon’s syndrome, which is a disease with strokes 
and livedo reticularis, as a spectrum of APS [29]. Libman-Sacks endocarditis in sys-
temic lupus erythematosus patients also has an accumulation of antiphospholipid 
antibodies in the subendothelial layer of the heart valves. However, the correlation 
with APS is not well established [30].
For patients with a diagnosis of APS, treatment as well as prophylaxis is 
required. However, there are patients who have met the diagnostic criteria but with 
no thrombotic events. In these patients, behavioral changes such as smoking and 
alcohol cessation, lipid control, diabetes management and nonuse of exogenous 
estrogens are the most important measures [27].
Avoiding prolonged immobilizations and other behaviors that predispose to 
thrombotic events is also recommended. Some authors advocate the use of aspirin 
without scientific consensus [28].
Primary prophylaxis with low-dose aspirin prophylaxis is usually prescribed to 
prevent thrombosis in women with recurrent miscarriages, but it does not prevent 
deep vein thrombosis in men with APS. In systemic lupus and secondary APS, 
hydroxychloroquine has been proven to have a protective effect against thrombosis, 
as well as a reduction in cholesterol and glycemia. Patients who undergo surgery and 
require prolonged immobilization require prophylactic heparinization, and in APS, 
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sometimes doses should be higher than usual due to resistance to anticoagulant 
effects. For treatment, as initial therapy, unfractionated heparin or low molecular 
weight heparin is used. Warfarin may also be used [28].
Because patients with APS and thrombosis are at high risk for recurrent throm-
boembolism episodes, prolonged oral anticoagulant therapy is the best option for 
attempting to prevent further episodes. The most used oral anticoagulant is warfa-
rin with a therapeutic goal of maintaining INR greater than or equal to 3 [31].
In cases of APS secondary to the underlying systemic disease, it should not 
open the treatment with systemic oral corticoid. Other agents that can be used are 
plasmapheresis, immunoglobulin and dapsone, among others [27].
In refractory and catastrophic cases that there is multiple organ infarction, anti-
coagulation combinations, steroids, plasmapheresis, intravenous immunoglobulin 
and fish oil derivatives can be used. Fibrinolytic agents have no proven benefit [28].
In case of pregnancy, the best alternative during this period is heparin associated 
with low doses of aspirin. Combined treatment is more effective to prevent miscar-
riages than just aspirin alone. Unfractionated heparin, low molecular weight heparin 
(enoxaparin 40 mg/day) and dalteparin 5000 UI/day can be used during this period. 
Warfarin should not be used in pregnant women. Accidental discovery of antiphospho-
lipid antibodies during pregnancy, with no clinical history of problems such as throm-
boembolic events or systemic lupus erythematosus, does not require treatment [28].
4.2 Blue finger syndrome
It is a sudden cutaneous manifestation in which the fingers, especially the 
toe, develop cyanotic and painful character. The priority etiology is embolic, but 
there may be other causes such as rheumatologic and neoplastic, among others. 
Treatment for this condition depends on the treatment of the underlying disease. 
However, general and local care such as limb warm-up, physical protection, treat-
ment of secondary infections are essential [32].
4.3 Acrocyanosis
Acrocyanosis is a disease resulting from chronic vasospasm that causes reflex 
vasodilation in the affected extremities, usually by medication or central nervous 
system disorders. It may be painful, cold, discolored, hyperhidrosis, paresthesia and 
even tingling. Like for blue finger syndrome, treatment is only supportive [27].
4.4 Erythromelalgia
Erythromelalgia is characterized by vasodilation of the extremities, especially 
in male children, and is usually associated with limb warm-up, pain and burning. 
It is believed that there is some change in calcium channels, so therapy is directed 
toward this focus.
In the case of primary erythromelalgia, anesthetics, antiarrhythmics, anticon-
vulsants and even oral magnesium may be used. In the case of secondary erythro-
melalgia, besides the treatment already discussed, the underlying disease needs to 
be controlled [27].
Its treatment includes topical drugs like 5% lidocaine and 0.075% capsaicin. 
For oral medications, we have amitriptyline 10 mg/day, gabapentin 900–1800 mg/
day, pregabalin 75 mg/day, flecainide 200 mg/day and buflomedil 200–330 mg/day. 
Tricyclic antidepressants, selective serotonin reuptake inhibitors and, in selected 
cases, acetylsalicylic acid, beta blockers and calcium channel antagonists may be 
excellent associations. In refractory cases, we may use epidural infusions of opioids, 
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bupivacaine and, in the latter case, sympathectomy. However, responses are quite 
variable and complete remission of symptoms is rarely observed [27, 33].
4.5 Livedo reticularis
Reticular livedo is a common dermatological manifestation in which the limb in 
question suffers a vasospasm and has a cyanotic, erythematous and erythematous-
violet coloration. When the blood plot does not have a confluent pattern, it is called 
a racemose livedo. In clinical practice, it may be isolated by cold or trauma or may 
be associated with some systemic diseases such as lupus erythematosus, sclero-
derma and HIV. Although it is more common in the limbs, it can also affect the 
trunk and there may be ulcerations. Cold stimulates vasospasm, when the cause is 
removed, however, over time, vessels may become permanently dilated and become 
permanently telangiectatic [27, 34].
The treatment of livedo, primarily, is protection against the cold. Vasodilators 
may be an alternative and corticosteroids should be avoided as much as possible. 
If there are ulcerations or a racemose livedo associated with antiphospholipid 
antibody syndrome, anticoagulation is recommended. When livedo is associated 
with some underlying disease, the management of the disease usually improves its 
manifestation. Other medications may be tried such as danazol, tissue plasminogen 
activator (tPA), pentoxifylline and antiplatelets. Immunosuppressants such as 
azathioprine and sympathectomy are reserved for refractory cases [27, 34, 35].
4.6 Raynaud’s phenomenon
It is a paroxysmal vasospastic disorder characterized by the simultaneous alter-
nation of pallor (vasoconstriction), cyanosis (blood stasis) and redness (compensa-
tory vasodilation).
We consider Raynaud’s disease (20% of the cases) when it occurs primarily and 
not associated with other acne. And we consider Raynaud’s phenomenon (80%) 
when it occurs secondary to another disease [27].
Treatment consists of treating the basic disease and quitting smoking. 
Protection against the cold is necessary to avoid triggering the frame. In idiopathic 
forms, the use of nifedipine 30–120 mg/day can be used. Other treatment modali-
ties may also be employed such as topical nitroglycerin, iloprost, losartan, serotonin 
receptor inhibitors, phosphodiesterase inhibitors, n-acetylcysteine, botulinum 
toxin, bosentan, platelet inhibitors and fibrinolytics. In refractory cases, sympa-
thectomy may be performed [27].
4.7 Erythema pernio or perniosis
Perniosis is a rare panniculitis that develops with painful erythematous-
violaceous nodules in young people more susceptible to cold. There is also a certain 
uncertain relationship with tobacco. Treatment, like other cold-related conditions, 
requires protection from the cold such as appropriate clothing, gloves, socks, boots 
and smoking cessation. Behavior changes and topical corticoid creams can help to 
heal the lesions. Some vasodilators may also be applied as nicotinic acid, nifedipine 
and pentoxifylline. In refractory cases, sympathectomy and UVB phototherapy may 
also be considered [36].
4.8 Livedoid vasculitis or Millian’s white atrophy
Livedoid vasculitis is one of the most common vasculopathies, described in 1929, 
and can affect up to about 5% of the healthy population, reaching 70% in patients 
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with venous ulcers. Some authors differentiate livedoid vasculitis from Millian’s 
white atrophy in relation to etiology. Livedoid vasculitis is persistent livedoid 
reticularis associated with an ulcer [37]. White atrophy is a white atrophy scar with 
a stellar pattern most common in the lower limbs of women aged 30–60 years that 
may or may not be associated with collagenases and neoplasia; however, the best-
established link is with chronic venous insufficiency [35].
The treatment for this disease is divided into some of the following groups:
• Vasodilators such as nifedipine [27, 35].
• Drugs stimulating endogenous fibrinolytic activity such as danazol, the 
activating factor of recombinant tissue plasminogen, rt-PA, low dose alteplase, 
associated or not with heparin and aspirin [27, 35].
• Drugs such as dipyridamole, cilostazol, the thienopyridine group (clopidogrel, 
ticlopidine hydrochloride, whether associated with aspirin) and sarpogrelate.
• Hemorheological drugs that decrease blood viscosity, increase red blood cell 
flexibility and improve circulation. From this group, the example is pentoxifyl-
line and buflomedil hydrochloride [27, 35].
• Modulating lymphocyte response therapy as systemic PUVA phototherapy [27].
• Other drugs such oral corticosteroids, intravenous immunoglobulin, cyclospo-
rine, hyperbaric oxygen therapy and intravenous iloprost [27].
For patients with any associated thrombophilia, warfarin, unfractionated 
heparin, low molecular weight heparin and even heparin minidoses may also be 
used [27].
4.9 Atherosclerosis obliterans
It is a chronic disease associated with diabetes that gradually occludes the vessel 
light. It affects the feet more than the hands in patients over 50 years. There is 
no specific treatment, but oral corticosteroids may be employed associated with 
diabetes with strict disease control. Behavioral change with diabetes mellitus 
improvement and antibiotic therapy, if secondary injuries, is the therapy of choice. 
Vasodilators do not have their proven efficiency. In severe cases, sympathectomy 
and vascular surgery may be used [38].
4.10 Thromboangiitis obliterans (Buerger’s disease)
The priority treatment is smoking cessation and rest. Iloprost IV may be an alterna-
tive to retard evolution. In many cases, amputation is required, with excision of the 
gangrenous fingers, sympathectomy and surgeries such as arterialization of the venous 
arch of the foot. The vascular surgeon is extremely important for follow-up [27, 39].
4.11 Malignant atrophic papulosis (Köhlmeier-Degos disease)
Malignant atrophic papulosis (MAP) is an obliterating endovasculitis of small- 
and medium-sized arteries that produces tissue infarction as its main feature. It 
is considered an uncommon disease of unknown cause and can affect the skin, 
gastrointestinal tract and central nervous system, and the involvement of these last 
two systems can be fatal [40].
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There is no fully effective treatment for the disease. Some authors use acetyl-
salicylic acid (300 mg daily) and/or dipyridamole (75 mg twice daily) as the first 
therapeutic modality, which facilitates blood perfusion. Other therapeutic options 
such as aspirin, heparin and warfarin can be used, however, aspirin is more associ-
ated with resurgence of lesions when discontinuing the drug [41].
More recently, studies have been conducted using eculizumab that have 
shown initial efficacy in skin and intestinal lesions, but the drug has not been 
able to prevent the development or progression of systemic manifestations. 
Subcutaneous treprostinil has been successfully tested in some cases with dra-
matic and sustained improvement in clinical status, although the response was 
not immediate. The mechanism of action of treprostinil in this scenario is not yet 
well understood [42, 43].
The use of corticosteroids, chloroquine or other immunosuppressants has 
proved unsatisfactory and has great potential to worsen the disease by unknown 
mechanism; therefore, they are not indicated [43].
4.12 Superficial thrombophlebitis
These are vascular inflammations with thrombus formation and consequent 
occlusion or may occur due to slow flow within a varicose vein. If thrombophlebitis 
is found in apparently normal superficial veins, attention should be paid to the pos-
sibility of underlying malignancy, thrombosing coagulopathy and silent deep vein 
thrombosis [44].
For therapeutic management, in cases of limited superficial thrombophlebitis 
below the knee, without evidence of deep vein thrombosis, compression by specific 
stockings and the use of nonsteroidal anti-inflammatory drugs are enough, provid-
ing symptomatic relief. However, if there is deep venous thrombosis or extension to 
the saphenofemoral or saphenopopliteal junctions, prophylactic use of low molecu-
lar weight heparin may be necessary [44].
5. Conclusion
Vasculitis and vasculopathies are a challenge physicians face on a daily basis. 
Due to rarity of the diseases all over the globe, the scientific community is not able 
to perform studies with a great number of patients and biological medications 
seem to be the promise to a cure or the disease control. These groups of drugs are 
relatively new and still expensive in most countries. Furthermore, more studies 
need to be developed and long follow-ups should be performed before they are 
considered gold-standard treatment. In the medical reality nowadays, despite any 
consideration, an early diagnosis can change the whole disease course and prevent 
inabilities, and even without cure, it is indispensable to control symptoms and 
provide a better quality of life to patients.
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